Why the study?
There is a need for a simple, effective, and cost-effective index for rapid risk stratification in ACS, prompting evaluation of the systemic immune inflammation index and its association with mortality in NSTEMI.
Does the systemic immune inflammation index (SII) predict all-cause mortality in patients with NSTEMI?
Does the systemic immune inflammation index (SII) predict all-cause mortality in patients with NSTEMI?
Answers are grounded in this paper and cite their sources.
The systemic immune inflammation index is significantly elevated in patients with NSTEMI compared to those with normal coronary arteries, suggesting potential utility as a simple biomarker for risk stratification.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Çayırlı et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: